IVBT (Innovation1 Biotech) Debt-to-EBITDA : -1.01 (As of Feb. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IVBT Innovation1 Biotech Inc IVBT
12 GF Score
Price $0.00
View Full Analysis

What is Innovation1 Biotech Debt-to-EBITDA?

Innovation1 Biotech IVBT 12 Debt-to-EBITDA is -1.01 as of Feb. 2024. GuruFocus rates IVBT with a GF Score™ of 12/100.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Innovation1 Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $0.05 Mil. Innovation1 Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $0.56 Mil. Innovation1 Biotech's annualized EBITDA for the quarter that ended in Feb. 2024 was $-0.60 Mil. Innovation1 Biotech's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2024 was -1.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Innovation1 Biotech's Debt-to-EBITDA or its related term are showing as below:

IVBT's Debt-to-EBITDA is not ranked *
in the Diversified Financial Services industry.
Industry Median: 5.755
* Ranked among companies with meaningful Debt-to-EBITDA only.

Innovation1 Biotech  (OTCPK:IVBT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Innovation1 Biotech Debt-to-EBITDA Related Terms

Innovation1 Biotech Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Innovation1 Biotech's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation1 Biotech Debt-to-EBITDA Chart

Innovation1 Biotech Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -0.46 -0.66 0.13 -0.01 -0.04

Innovation1 Biotech Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.15 -0.01 -0.77 -1.01

IVBT vs NVIV, PXMD, SCNI: Debt-to-EBITDA Comparison

For the Shell Companies subindustry, Innovation1 Biotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovation1 Biotech Debt-to-EBITDA vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Innovation1 Biotech's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Innovation1 Biotech's Debt-to-EBITDA falls into.


IVBT
12GF Score
Innovation1 Biotech Inc IVBT
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innovation1 Biotech Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Innovation1 Biotech's Debt-to-EBITDA for the fiscal year that ended in Aug. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.01 + 0.219) / -5.684
=-0.04

Innovation1 Biotech's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.05 + 0.555) / -0.6
=-1.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Feb. 2024) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of -1.01 mean?
Innovation1 Biotech (IVBT) has a Debt-to-EBITDA of -1.01 as of Feb. 2024. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Innovation1 Biotech.
Is Innovation1 Biotech's Debt-to-EBITDA too high?
Innovation1 Biotech's current Debt-to-EBITDA is -1.01. Overall, Innovation1 Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Innovation1 Biotech's Debt-to-EBITDA compare to NVIV and PXMD?
Innovation1 Biotech's Debt-to-EBITDA of -1.01 can be compared against companies in the Diversified Financial Services industry. The industry median Debt-to-EBITDA is 5.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Diversified Financial Services company?
The median Debt-to-EBITDA among Diversified Financial Services companies is 5.76, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Innovation1 Biotech. For the Diversified Financial Services industry, the median Debt-to-EBITDA is 5.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovation1 Biotech's current Debt-to-EBITDA is -1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation1 Biotech stock overvalued right now?
Innovation1 Biotech (IVBT) has a current Debt-to-EBITDA of -1.01. The current Debt-to-EBITDA is -1.01. Innovation1 Biotech's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Innovation1 Biotech (IVBT), the current Debt-to-EBITDA is -1.01 as of Feb. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation1 Biotech Business Description

Address 7 Grand View Avenue, Somerville, MA, USA, 02143
Innovation1 Biotech Inc is a shell company.
12GF Score

Get the complete analysis for IVBT

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price